15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
12 citations
,
November 2006 in “Journal of thoracic oncology” A cancer patient's eyelashes grew excessively without other common side effects after taking the cancer drug erlotinib.
5 citations
,
March 2014 in “Journal of The American Academy of Dermatology” The study suggests hormonal factors may play a role in Frontal Fibrosing Alopecia and that treatments like oral antiandrogens and steroids could be beneficial.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
June 2025 in “The Journal of Dermatology” Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
January 2025 in “Dermatologic Therapy” Baricitinib effectively promotes hair regrowth in alopecia areata patients with mild side effects.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
February 2023 in “JAAD case reports” Reducing immunosuppression and using antiviral creams improved the woman's skin condition.
December 2020 in “American Journal of Transplantation” Early recognition and treatment of VATS in transplant patients improve outcomes.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
15 citations
,
November 2009 in “Clinical and Experimental Dermatology” Bimatoprost helped a girl grow her eyelashes back quickly and without serious side effects.
4 citations
,
March 2025 in “The Journal of Dermatology” Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
2 citations
,
February 2025 in “Archives of Dermatological Research” Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
October 2025 in “Journal of Clinical Medicine” Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
4 citations
,
March 2023 in “Current Oncology” Scalp cooling is the only FDA-approved method to prevent hair loss from chemotherapy, but other treatments like minoxidil and PRP are being tested.
13 citations
,
January 2016 in “Journal of Ophthalmology” A new eyelid shampoo improved eyelid hygiene and eyelash length in people with Meibomian Gland Dysfunction.
9 citations
,
July 2017 in “Journal of medical case reports” Ruxolitinib treatment may cause eyelash growth.
38 citations
,
October 2014 in “British journal of dermatology/British journal of dermatology, Supplement” Bimatoprost solution is effective and safe for long-term use in treating eyelash thinning.
29 citations
,
May 2010 in “Ophthalmology” Bimatoprost gel makes eyelashes grow longer, but may cause side effects and should be monitored by an eye doctor.
12 citations
,
September 2012 in “Plastic and Reconstructive Surgery” Adding de-epithelialization to the follicular isolation technique improves hair transplant results for eyebrows and eyelashes.
11 citations
,
August 2012 in “Canadian journal of ophthalmology” Eyelash alopecia areata often goes undiagnosed and can lead to complete eyelash regrowth, especially in younger patients.
6 citations
,
October 2022 in “American journal of clinical dermatology” The review shows how to properly diagnose and treat the loss of eyebrow and eyelash hair.
2 citations
,
February 2016 in “British Journal of Dermatology” Bimatoprost solution 0.03% is effective for treating sparse eyelashes.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
3 citations
,
July 2010 in “Archives of internal medicine” A woman kept her eyelashes during chemotherapy possibly because of her glaucoma eye drops.
14 citations
,
November 2009 in “Clinical and experimental dermatology” Topical prostaglandin E2 can help treat both alopecia areata and vitiligo.